• search
In vivo Pharmacology Studies and Services In vivo Pharmacology Studies and Services

In vivo Pharmacology Studies and Services

We are an efficient partner for in vivo pharmacology services with our experience in multiple therapeutic areas, target specific models, and a team of highly competent scientists.

In vivo pharmacology is essential to evaluate the complex physiological effects of a drug in the living organism. In vivo pharmacology studies are offered by Aurigene to assess the effectiveness and early toxicity of small compounds and large molecules. Our in vivo pharmacology services are backed by an AAALAC accredited vivarium.     

Our expanding disease models include pain management, inflammation & auto immune diseases, metabolic disorders, oncology etc.

Speak to our experts

Few therapeutic areas where we offer pharmacology discovery services are highlighted below:

Pain Models and Measurements

Aurigene has successfully collaborated with the world’s top pharmaceutical companies for pain drug discovery. Our expertise and experience allow us to offer an extensive portfolio of services supporting drug discovery and development. We match the industry’s needs in the domains of:

  • Acute and chronic inflammatory pain
  • Visceral pain
  • Arthritic pain
  • Neuropathic pain
Type​Animal ModelSpecies/ strain​Validation standard​
Acute ModelsAcetic acid induced writhingMale Swiss albino mice​Indomethacin/Tramadol​
Carrageenan-induced mechanical hyperalgesia ​Male Wistar rat​Celecoxib​
Complete Freund’s adjuvant (CFA) induced thermal hyperalgesiaMale Sprague Dawley rat​Indomethacin​
Arthritic Pain​CFA-induced mono arthritis pain​Male Sprague Dawley rat​Naproxen​
Monoidoacetate-induced osteoarthritis pai​Male Sprague Dawley rat ​Diclofenac​
Neuropathic PainPartial sciatic nerve ligation​Male Wistar rat​Gabapentin ​

Inflammation and Auto-immune Disorders

Our team of experts have developed in vivo models for autoimmune and inflammatory diseases. We offer inflammation animal models associated with:

  • Neurological diseases
  • Respiratory diseases
  • Arthritis
  • Skin diseases
  • Gastrointestinal diseases and
Type​Animal ModelSpecies/ strain​Validation standard​
Acute ModelsLPS-induced systemic inflammation (Plasma TNF-α)Female wistar rat/ Male BALB/c mice​Roflumilast / Theophylline​
LPS-induced systemic inflammation (Plasma IL-17 )​Male C57BL/6 mice​​Digoxin​
LPS-induced paw edema​Female wistar rat​Nimesulide
Carrageenan-induced paw edema​Male wistar rat​​Celecoxib​
Acute Arthus reaction​Female C57BL mice​Kinase inhibitor​
The SCF-induced systemic histamine release model​Female BALB/c mice​Anti C-KIT antibody
Mouse passive cutaneous anaphylaxis model​Female C57BL/6 mice​Dexamethasone
TNF + Zvad induced hypothermia​Female C57BL miceKinase inhibitor
ArthritisCollagen-Induced Arthritis (Prophylactic)​Female Lewis rat​Leflunomide​
Collagen-Induced Arthritis (Therapeutic)​​Female Lewis rat​Enbrel, Dexamethasone​​
Adjuvant-Induced Arthritis (Prophylactic)​​​Female Lewis rat​Celecoxib​
Medial Meniscus Induced Tear Osteo Arthritic model​Female Lewis rat​Celecoxib​​​
Dermatitis & PsoriasisDNFB-induced contact dermatitis ​​Female CD1 mice​Leflunomide​ ​
Oxazolone-induced contact dermatitis​Male SD rat​Dexamethasone
Imiquimod-induced psoriasis model​​Female Balb/c mice​Dexamethasone /Anti mouse IL-17 anti body
IL-23-induced dermatitis model​Female Balb/c mice​​Tofacitinib/​
ColitisDextran Sulphate Sodium induced colitis​C57BL/6 mice​​​cyclosporin​​
Trinitrobezene sulphonic acid-induced colitis ​Female wistar rat/ BALB/c mice​Dexamethasone
FibrosisUnilateral ureteral obstruction model​Male C57BL/6 miceNecrostatin-1​
Acne​Hamster ear sebaceous gland model​Female Hamsters​spironolactone​
Asthma​Ovalbumin/LPS induced neutrophilic asthma model​Male C57BL/6 mice​Digoxin​
MS​MOG-induced EAE model in C57BL/6​Female C57BL/6 mice​Copaxone

Metabolic Disorders (Diabetes, Obesity and Atherosclerosis)

The team has vast experience in conducting customized metabolic disorder animal models.

Type​Strain-SpeciesActivity/test Model​​Validating/Standards​​
MD​ (Diabetes and Obesity)Mice and rats​OGTT, IPGTT, IVLTT, and Euglycemic clamp study​​Pioglitazone/Exenatide​
Swiss albino mice / Wistar rats/CD1 mice​​Acute food intake modulating activity ​Rimonabant/ PYY 3-36/Liraglutide
CD1 mice​3 days of administration of food intake and body weight lowering activity​PYY 3-36​
db/db mice​Blood glucose lowering and anti-dyslipidemic activityPioglitazone/ liraglutide
Zucker fa/fa ratsAnti-dyslipidemic activity and insulin-sensitizing activity​Fenofibrate/Pioglitazone​
ob/ob mice​Body weight lowering and insulin-sensitizing activity​​Metformin/Pioglitazone
C57BL/6 - DIO miceBody weight lowering activity​Rimonabant/PYY 3-36
CV (Atherosclerosis)LDLr -/-MicAnti-atherosclerotic activity​Fenofibrate​
Swiss albino miceLipid-lowering activityFenofibrate ​​
High-fat-fed Sprague Dawley ratsAcute lipid (TC, TG) lowering activity​Fenofibrate
Golden Syrian HamsterHDL elevating activity​Torcetrapib ​

Oncology Animal Model

Aurigene has significant experience in oncology drug discovery. We offer a large collection of tumor models for small and large molecule drug discovery.

Cancer type ​Cell line​Mice ​​​Model type ​​
Lung cancer, NSCLCA549, Known to be KRAS mutant and EGFR wild type ​Ncr nude mice​​Xenograft, subcutaneous​
Multiple Myeloma ​H929​​NOD SCID mice ​Xenograft, subcutaneous​
Breast cancer​MCF-7 cells are ER+, progesterone receptor-positive, and HER2 negative.​​Ncr nude mice ​​​Xenograft, subcutaneous​
Prostate cancer​22RV1, cell line has been derived from a human prostatic carcinoma xenograft, CWR22RNcr nude miceXenograft, subcutaneous​
Colon cancer​COLO 205 non metastatic ​​Ncr nude mice​​Xenograft, subcutaneous​
Leukemia​MV-4-11, human biphenotypic B myelomonocytic leukemia​​​Ncr nude miceXenograft, subcutaneous​​
Colon cancer​CT26​​BALB/c miceSyngeneic, subcutaneous​     
Established model ​
Ovarian cancer​SKOV-03​​Ncr nude miceXenograft, subcutaneous     
Established model​
Acute myeloid leukemia​MOLM-13​​NOD SCID miceXenograft, subcutaneous     
Established model​

Miscellaneous models

  • Mouse/ rat whole blood and splenocyte assays with different stimulants (LPS, NECA) and evaluation of cytokines and biomarkers using flow cytometer.
  • Oxidative stress markers evaluation in rats administered with repeat intravenous Iron formulation.
  • Evaluation of test compounds potential in modulating serum Iron and hepcidin expression modulation in restricted iron diet fed rats.
  • Evaluation of test compounds potential in muscle regeneration in thermal injury mice model.
  • Anti-acne potential evaluation of test compounds in hamsters ear sebaceous gland model.
  • Evaluation of test compounds efficacy in mice post-operative ileus model.
  • Evaluation of test compounds efficacy in gastric emptying and intestinal motility in mice model

Why Aurigene Pharmaceutical Services?

Experience in submissions to the US FDA and DCGI

Highly qualified and experienced scientists

Capacity to handle more than 600 rodents at a given time

AAALAC accredited vivarium

Virtual Tour

Neoantigen Specific T cells For Cancer Immunotherapy

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. The success of immune checkpoint blockade...

Read More

Biologics Process Development Services

Our strength is built on a deep understanding of cell culture, protein chemistry and an integrated analytics platform enabling a robust, scalable and controlled process. ...

Read More

Development of quick quantification method for muscle injury recovery evaluation in thermal injury mice model

Challenges: The evaluation of Evans Blue Dye (EBD) by fluorescence measurements of cryosections of individual muscle sections, and its quantification by auto fluorescence is a laborious and time-consuming process. Study design: Both sham and thermal injury techniques were followed. The evaluation of EBD was done to assess the effectiveness of two compounds in the...

Read More

Synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3- dihydroquinazolin-4(1H)-one via molybdenum hexacarbonyl mediated CO gas- and ligand free carbonylative reactions


Carbon monoxide gas and ligand-free conditions were developed for the synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3-dihydroquinazolin4(1H)-one via catalytic carbonylation with molybdenum hexacarbonyl as an efficient carbonylating agent for the three-component reaction of isatoic anhydride, amine, iodobenzene. Mo(CO)6 is a solid carbon monoxide source. The quinazoli...

Read More
View All

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.